Logo Scientific Seminars

ESMO 2023 | Immediate Globally-Reaching Post-ESMO Education in Breast Cancer: Clinical updates up through ESMO 2023 in advancements of HER2+, HER2-Low, HR+ and TNBC mBC

This Curriculum has the aim to evaluate the landscape of BC management, delving into the latest breakthroughs, therapies, and strategies that have transformed our approach to this complex and chronic condition.

This Curriculum is designed to offer you a thorough understanding of the wide range of treatment modalities available. From conventional methods to cutting-edge innovations, our goal is to equip you with the insights needed to make informed decisions for optimizing BC management, including use of ADCs, immunotherapy, Parp-inhibitors and a potential therapeutic algorithm for HER 2-low breast cancer.


  • Discuss the most recent evidence -based recommendations, guidelines, and clinical trial presentations of HR+ breast cancer
  • Assess the efficacy and safety of new treatment approaches, specifically antibody-drug conjugates, in the management of patients with TNBC, HR+  HER2+, HER2-Low BC


Oncology clinicians and specifically those actively involved in the treatment of breast cancer








A collaboration between Scientific Seminars International Foundation and AXDEV Global Inc. in Join Providership with RealCME and Academic CME

Share on social


Pantano Francesco

Sara Bassetti | Progamme Manager | sara.bassetti@scientificseminars.com

This educational program is made possible thanks to an independent educational grant received from Daiichi Sankyo, Inc.



Scientific Seminars Foundation
My Agile Privacy
This website uses technical and profiling cookies. Clicking on "Accept" authorises all profiling cookies. Clicking on "Refuse" or the X will refuse all profiling cookies. By clicking on "Customise" you can select which profiling cookies to activate.
Warning: some page functionalities could not work due to your privacy choices